Kerigo Ndirangu

Breast cancer (BC) is the most common cancer occurring in women [1]. In 2020, an estimated 2.3 million women were diagnosed with BC and 684,996 women died from BC [1] worldwide. Survival depends on the stage of disease as well as by BC subtype [2]. Overall, the 5-year relative survival probability for patients with localized disease is 99.3%, reduced to 86.3% for those with regional disease and 31.0% for those with distant disease [2].

Discussion/conclusion While the impact of immunotherapy-induced ADAs on treatment outcomes of psoriasis or rheumatoid arthritis is well characterized,98–101 research examining the immunogenicity of ADAs in the treatment of cancer is at an early stage.

Background The incidence of breast cancer (BC) has continued to rise rapidly and is a leading cause of cancer death. Human epidermal growth factor receptor 2–positive (HER2+) BC is approximately 20% of all invasive BC. Recent advances in chemotherapy and targeted treatments against HER2 have significantly improved the prognosis of HER2+ BC. Pertuzumab (Pmab) + trastuzumab (Tmab) + docetaxel (DOC) has been approved for the first-line (1L) treatment of patients with HER2+ metastatic BC.